Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Xiaozhou Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-5748-5559; OpenAlex author ID A5102215521. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 3

  1. The role of APOBEC mutagenesis in the progression and therapeutic guidance of pancreatic cancer. Co-author DOI 10.1016/j.ygeno.2025.111098↗
  2. CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism. First author DOI 10.1002/advs.202206335↗
  3. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms. Co-author DOI 10.1016/j.canlet.2021.07.024↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weishuai Liu · 3 shared papers, 2021–2025 · strength 0.50
  2. Chongbiao Huang · 2 shared papers, 2021–2023 · strength 0.26
  3. Jihui Hao · 2 shared papers, 2021–2023 · strength 0.26
  4. Weihao Zhang · 1 shared paper, 2025 · strength 0.25
  5. Bo Ni · 1 shared paper, 2025 · strength 0.25
  6. Yongjie Xie · 1 shared paper, 2025 · strength 0.25
  7. Chao Wu · 1 shared paper, 2023 · strength 0.14
  8. Shengnan Li · 1 shared paper, 2023 · strength 0.14
  9. Bo Tang · 1 shared paper, 2023 · strength 0.14
  10. Peng Xie · 1 shared paper, 2023 · strength 0.14
  11. Shengyu Yang · 1 shared paper, 2021 · strength 0.11
  12. Liangliang Wu · 1 shared paper, 2021 · strength 0.11
  13. Xiuchao Wang · 1 shared paper, 2021 · strength 0.11
  14. Song Gao · 1 shared paper, 2021 · strength 0.11
  15. Tiansuo Zhao · 1 shared paper, 2021 · strength 0.11
  16. Ying Ma · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.